向接受无效重症监护的患者提供血液制品。
Blood Products Provided to Patients Receiving Futile Critical Care.
作者信息
Neville Thanh H, Ziman Alyssa, Wenger Neil S
机构信息
Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
出版信息
J Hosp Med. 2017 Sep;12(9):739-742. doi: 10.12788/jhm.2820.
The number of hospitalized patients receiving treatment perceived to be futile is not insignificant. Blood products are valuable resources that are donated to help others in need. We aimed to quantify the amount of blood transfused into patients who were receiving treatment that the critical care physician treating them perceived to be futile. During a 3-month period, critical care physicians in 5 adult intensive care units completed a daily questionnaire to identify patients perceived as receiving futile treatment. Of 1136 critically ill patients, physicians assessed 123 patients (11%) as receiving futile treatment. Fifty-nine (48%) of the 123 patients received blood products after they were assessed to be receiving futile treatment: 242 units of packed red blood cells (PRBCs) (7.6% of all PRBC units transfused into critical care patients during the 3-month study period); 161 (9.9%) units of plasma, 137 (12.1%) units of platelets, and 21 (10.5%) units of cryoprecipitate. Explicit guidelines on the use of blood products should be developed to ensure that the use of this precious resource achieves meaningful goals.
接受被认为是无效治疗的住院患者数量并不少。血液制品是宝贵的资源，是为帮助其他有需要的人而捐赠的。我们旨在量化输给那些接受重症监护医师认为是无效治疗的患者的输血量。在3个月的时间里，5个成人重症监护病房的重症监护医师每天填写一份问卷，以确定被认为接受无效治疗的患者。在1136名重症患者中，医师评估123名患者（11%）接受无效治疗。在这123名患者中，有59名（48%）在被评估为接受无效治疗后接受了血液制品：242单位的浓缩红细胞（PRBCs）（占3个月研究期间输给重症监护患者的所有PRBC单位的7.6%）；161单位（9.9%）的血浆，137单位（12.1%）的血小板，以及21单位（10.5%）的冷沉淀。应制定关于血液制品使用的明确指南，以确保这种宝贵资源的使用能够实现有意义的目标。
Zotero 插件